DOBUTAMINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Dobutamine Hydrochloride, and what generic alternatives are available?
Dobutamine Hydrochloride is a drug marketed by Baxter Hlthcare, Dr Reddys, Hainan Poly, Hikma, Hospira, Luitpold, Teligent, Teva Parenteral, Watson Labs, and Watson Labs Inc. and is included in fifteen NDAs.
The generic ingredient in DOBUTAMINE HYDROCHLORIDE is dobutamine hydrochloride. There are fourteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the dobutamine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dobutamine Hydrochloride
A generic version of DOBUTAMINE HYDROCHLORIDE was approved as dobutamine hydrochloride by HOSPIRA on November 29th, 1993.
Summary for DOBUTAMINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 10 |
NDAs: | 15 |
Finished Product Suppliers / Packagers: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 102 |
Clinical Trials: | 115 |
Patent Applications: | 740 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in DOBUTAMINE HYDROCHLORIDE? | DOBUTAMINE HYDROCHLORIDE excipients list |
DailyMed Link: | DOBUTAMINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for DOBUTAMINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Wuhan Union Hospital, China | Phase 2/Phase 3 |
Ain Shams University | Phase 2/Phase 3 |
University of Chicago | Early Phase 1 |
Pharmacology for DOBUTAMINE HYDROCHLORIDE
Drug Class | beta-Adrenergic Agonist |
Mechanism of Action | Adrenergic beta-Agonists |